Outlook Therapeutics, Inc. - Common Stock (OTLK)
1.7350
-0.0950 (-5.19%)
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases
The company specializes in the research and advancement of therapies aimed at addressing significant unmet medical needs in ophthalmology. Through its proprietary drug pipeline, Outlook Therapeutics is committed to enhancing the quality of life for patients affected by various retinal conditions, striving to bring new possibilities and improved outcomes to vision care.
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQOTLK) on behalf of long-term stockholders following a class action complaint that was filed against Outlook on November 3, 2023 with a Class Period from December 29, 2022 to August 29, 2023. Our investigation concerns whether the board of directors of Outlook have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · October 11, 2024
![](https://www.marketbeat.com/logos/articles/med_20240710145714_3-beaten-down-pharmaceuticals-with-catalysts-for-h.jpg)
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.
Via MarketBeat · July 11, 2024
![](https://www.marketbeat.com/images/MarketBeat-icon-256x256.png)
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via MarketBeat · June 22, 2024
![](https://www.marketbeat.com/logos/articles/med_20240618135722_outlook-therapeutics-analysts-forecast-over-500-st.jpg)
Outlook Therapeutics (NASDAQOTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target.
Via MarketBeat · June 19, 2024
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 1, 2024
![](https://mms.businesswire.com/media/20240101189265/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQOTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline.
By The Rosen Law Firm, P.A. · Via Business Wire · January 1, 2024
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 31, 2023
![](https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg)
NEW YORK, Dec. 31, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 31, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 30, 2023
![](https://mms.businesswire.com/media/20231229645531/en/538768/22/BES_Mark.jpg)
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQOTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire, P.C. · Via Business Wire · December 29, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 29, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 28, 2023
![](https://mms.businesswire.com/media/20231228392117/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQOTLK) securities between August 3, 2021 and August 29, 2023, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · December 28, 2023
![](https://ml.globenewswire.com/media/8628babf-2ea4-4b8a-a60b-260db109bfa2/small/logo-png.png)
If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 27, 2023
![](https://ml.globenewswire.com/media/5d514042-8326-4555-8ad7-f6cc765ecfcd/small/bl-new-logo-jpg.jpg)
NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · December 27, 2023
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Dec. 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQOTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 25, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 25, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 23, 2023
![](https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg)
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 22, 2023
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQOTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 21, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 20, 2023
![](https://ml.globenewswire.com/media/8628babf-2ea4-4b8a-a60b-260db109bfa2/small/logo-png.png)
If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 19, 2023
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 18, 2023
![](https://ml.globenewswire.com/media/5d514042-8326-4555-8ad7-f6cc765ecfcd/small/bl-new-logo-jpg.jpg)
NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · December 18, 2023
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Dec. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQOTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 16, 2023